The Combining of Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors as First-Line Treatment for Advanced Stage Hepatocellular Carcinoma

Aim: Hepatocellular carcinoma (HCC) is one of the most common cancers. Tyrosine kinase inhibitors (TKIs), including sorafenib (SOR) and lenvatinib (LEN), as well as immune checkpoint inhibitors (ICIs), including nivolumab (NIVO) and pembrolizumab (PEMBRO), have been approved for the treatment of adv...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Shou-Wu, Yang, Sheng-Shun, Lien, Han-Chung, Peng, Yen-Chun, Tung, Chun-Fang, Lee, Teng-Yu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9409639/
https://www.ncbi.nlm.nih.gov/pubmed/36013120
http://dx.doi.org/10.3390/jcm11164874

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9409639/
https://www.ncbi.nlm.nih.gov/pubmed/36013120
http://dx.doi.org/10.3390/jcm11164874

Ejemplares similares